Other

Alla Chem, LLC

Eil Therapeutics, Inc.

R-Pharm Joint Stock Company (R-Pharm, Jsc)

Asavi LLC

R-Pharm Overseas Inc.

Ivashchenko, Andrey Alexandrovich

R-Pharm International LLC

Savchuk, Nikolay Filippovich

Ivachtchenko, Alexandre Vasilievich

Ivachtchenko, Alena Alexandrovna

Repik, Alexey Evgenievich

Alexandre Vasilievich Ivachtchenko

Oleg Dmitrievich Mitkin

Andrey Alexandrovich Ivashchenko

Nikolay Filippovich Savchuk

Vadim Bichko

Ruben Abagyan

Sergey Yevgenievich Tkachenko

Alexei Pushechnikov

Alena Alexandrovna Ivachtchenko

Vladislav Zenonovich Parchinsky

Polo Chun-Hung Lam

Nikolay Savchuk

Andrew Orry

Volodymyr Kysil

Ilya Okun

Yan Lavrovsky

Vasily Ignatiev

Madina Georgievna Kadieva

Dmitri Vladimirovich Kravchenko

Ilya Andreevich Ivachtchenko

Alexey Evgenievich Repik

Mikhail Airatovich Chafeev

Evgueni Borisovich Frolov

Alexandre Viktorovich Demin

Dmitry Vladimirovich Kravchenko

Anton Aleksandrovich Vorobev

Vadim Valilievich Bichko

Oleg Dimitrievich Mitkin

Andrey Sergeevich Trifilenkov

Ilya Matusovich Okun

Vadim Vasilievich Bichko

Vasily Gennadievich Ignatiev

The present invention relates to a novel Noradrenergic and Specific Serotonergic Anxiolytic and Antidepressant (NaSSA) and a method for the production and use thereof for treating mental disorders. The subject of this invention is a novel noradrenergic and specific serotonergic drug for the treatment of mental disorders in humans, which is 2,8-dimethyl-5-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole hydrochloride (A·HCl), a polymorphous modification thereof, and methods for the production and use thereof.

Noradrenergic and specific serotonergic anxiolytic and antidepressant, method for the production and use thereof

The present invention is generally directed to inhibitors of BCL-2 proteins useful in the treatment of diseases and disorders modulated by said enzyme and having the Formula (I):

Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors

Compounds having tetrahydroindolizine-1-carboxamide as BCL-2 inhibitors

The present application relates to the new the pharmaceutical combination therapy and prevention of SARS-CoV-2 and/or disease associated with this infection, including viral and bacterial pneumonia and COVID-19, using aprotinin (APR), ribavirin and/or nirmatrelvir (NIMR), the pharmaceutical kit and the pharmaceutical composition for this pharmaceutical combination therapy and prevention of SARS-CoV-2 and/or disease associated with this infection, including COVID-19.

Pharmaceutical combination therapy and prevention with aprotinin + nirmatrelvir of SARS-CoV-2 and/or disease associated with this infection, including COVID-19

Novel MEK1, MEK2 and MEK1/2 inhibitors which have lower toxicity in long-term dosage, including the novel compound N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]-phenyl}-cyclopropanecarboxamide dimethyl sulfoxide solvate according to formula 1: 

N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-D]pyrimidin-1-YL]-phenyl}-cyclopropanecarboxamide dimethyl sulfoxide solvate as an MEK1/2 inhibitor

The present invention relates to a prodrug and application thereof for the treatment of hepatitis C virus in patients. The prodrug of general formula 1, its stereoisomer, isotopically enriched analog, or crystalline or polymorphic form, 

Prodrug of an HCV NS5B polymerase inhibitor and method of production and application thereof

Nucleosides and nucleotides (nucleos(t)ides) have been in clinical use for almost 50 years and have become cornerstones of treatment for patients with viral infections or cancer. The approval of several additional drugs over the past decade demonstrates that this family still possesses strong potential. Therefore nucleos(t)ide are of great interest as promising chemotherapeutic agents, including: 2'-deoxy-L-uridine (CAS31501-19-6), 2&#x2032;-deoxy-D-uridine (CAS951-78-0), telbivudine (CAS3424-98-4), zidovudine (AZT, CAS30516-87-1), trifluridine (CAS70-00-8), clevudine (CAS163252-36-6), PSI-6206 (CAS863329-66-2), 2&#x2032;-(S)-2&#x2032;-chloro-2&#x2032;-deoxy-2&#x2032;-fluorouridine (CAS1673560-41-2), ND06954 (CAS114248-23-6), stavudine (CAS3056-17-5), 5-ethynyltavudine (Festinavir, CAS634907-30-5), torcitabine (CAS40093-94-5), (&#x2212;)-beta-D-(2R,4R)-dioxolane-thymine (DOT, 1-((2R,4R)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)-5-methyl-2,4(1H,3H)-pyrimidinedione, CAS No. 127658-07-5), 2-(6-amino-purin-9-yl)-ethanol (CAS707-99-3), 2&#x2032;-C-methylcytidine (CAS20724-73-6), PSI-6130 (CAS817204-33-4), gemcitabine (CAS95058-81-4), 2&#x2032;-chloro-2&#x2032;-deoxy-2&#x2032;-fluorocytidine (CAS1786426-19-4), 2&#x2032;,2&#x2032;-dichloro-2&#x2032;-deoxycytidine (CAS1703785-65-2), 2&#x2032;-C-methylcytidine (CAS20724-73-6), PSI-6130 (CAS817204-33-4), lamivudine (3TC, CAS134678-17-4), emtricitabine (CAS143491-57-0), 2&#x2032;-deoxyadenosine (CAS958-09-8), 2&#x2032;-deoxy-&#x3b2;-L-adenosine (CAS14365-45-8), 2&#x2032;-deoxy-4&#x2032;-C-ethynyl-2-fluoroadenosine (CAS865363-93-5), didanosine (CAS69655-05-6), entecavir (CAS209216-23-9), FMCA (CAS1307273-70-6), dioxolane-G (DOG, CAS145514-01-8), &#x3b2;-D-2&#x2032;-deoxy-2&#x2032;-(R)-fluoro-2&#x2032;-&#x3b2;-C-methylguanosine (CAS No 817204-45-8), abacavir (ABC, CAS136470-78-5), dioxolane-A (DOA, CAS #145514-02-9), [(2R,4R)-4-(6-cyclopropylamino-purin-9-yl)-[1,3]dioxolan-2-yl]-methanol (CAS1446751-04-7), amdoxovir (AMDX, CAS145514-04-1), (R)-1-(6-amino-purin-9-yl)-propan-2-ol (CAS14047-28-0), and [(2S,5R)-5-(6-amino-purin-9-yl)-4-fluoro-2,5-dihydro-furan-2-yl]-methanol. Macroheterocyclic nucleoside derivative and its analog of the general formula 1 or general formula 2, a stereoisomer, isotope-enriched analog, pharmaceutically acceptable salt, hydrate, solvate, or crystalline or polymorphic form thereof, wherein: wherein: Ris the substituent selected from H, F, Cl, CH, OH;

Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof

Compound represented by formula 1: or a pharmaceutically acceptable salt, a hydrate, a crystalline form, or a stereoisomer thereof, wherein:R1 is hydrogen, tert-butoxycarbonyl, where R11 is an optionally substituted C-Calkyl, an optionally substituted C-Ccycloalkyl, or an optionally substituted C-Calkyloxy, and arrows (&#x2190;) indicate the position of substituents attachment;R2 is hydrogen, halogen, or C-Calkyl;R3 is an optionally substituted aryl, an optionally substituted aryloxy, an optionally substituted arylsulfanyl, an optionally substituted arylamino, or an optionally substituted nitrogen hetaryl; 

Pan-genomic inhibitors of NS5A protein encoded by HCV, pharmaceutical compositions, intermediates for inhibitor synthesis, and their synthesis and application methods

The present invention relates to a method of antagonizing a 5-HTserotonin receptor, comprising administering to the cell a compound of formula 1.2, or a pharmaceutically acceptable salt thereof, wherein: Ris a C-Calkyl; The invention also relates to pharmaceutical compositions and method for treating a cognitive disorder or neurodegenerative disease in a subject in need thereof comprising administering an effective dose to the subject of a compound of formula 1.2 according to claim, or a pharmaceutically acceptable salt thereof.

Substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles, methods for use thereof

The present invention relates to novel antiviral active 5-{4-[1H-imidazol-5-ylaryl(or hetaryl)]-buta-1,3-diynyl}-1H-imidazoles of the general formula 1 and pharmaceutically acceptable salt thereof, pharmaceutical composition, antiviral medicament, therapeutic kit for prophylaxis and treatment of hepatisis C virus diseases, and method for prophylaxis and treatment of hepatisis C. wherein:Rand R&#x2014;represent optionally identical radicals selected from 2.1 and 2.2, where an asterisk (*) denotes the position of attachment to the imidazole fragment, (S) and (R) are types of chiral centers; Ris isopropyl or phenyl radicals;Ar an aromatic or heteroaromatic diradical.

Substituted azoles, antiviral active component, pharmaceutical composition, method for preparation and use thereof

The invention relates to pharmacology and medicine, more particularly to novel pharmaceutical compositions and pharmaceutical kits for treating bacterial infections, and to novel method for treating diseases caused by bacterial infections including tuberculosis. The pharmaceutical composition is disclosed comprising Rifamycin and interferon inducer in pharmacologically effective doses, and also pharmaceutical kit for treating diseases caused by bacterial and healthcare acquired infections, comprising pharmacologically effective doses of Rifamycin in the form of a tablet, a capsule or an injection, interferon inducer in the form of a tablet, a capsule or an injection, and instruction for administration of the components of this pharmaceutical kit.

Pharmaceutical composition and kit for treating bacterial infections

The invention relates to the field of pharmaceutics, in particular, to solid pharmaceutical composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol or pharmaceutically acceptable salt thereof, stabilizer, lubricant and filler; to method for preparation of pharmaceutical composition, to medicaments for immune suppression and treating multiple sclerosis. 2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol represents an immune modulator, which causes redistribution of lymphocytes from blood flow into secondary lymphoid tissue that leads to immune suppression. The invention provides uniform distribution of the active ingredient in the solid composition, high stability and improved flowability of the solid pharmaceutical composition. Due to the improved flowability the compositions suggested in the invention can be used on automated equipment.

Pharmaceutical composition having improved flowability, medicinal agent, and method for producing and using same

The present invention relates to novel cyclic N,N'-diarylurea&#x2014;androgen receptor antagonist, anti-cancer agent, pharmaceutical composition, medicament, and method for treatment of breast cancer disease. Cyclic N,N&#x2032;-diarylthioureas or N,N&#x2032;-diarylureas of the general formula 1, their optical (R)- and (S)-isomers and pharmaceutically acceptable salts thereof exhibiting properties of androgen receptor antagonists have been proposed, 

Cyclic N,N'-diarylthiourea&#x2014;androgen receptor antagonist, anti breast cancer composition and use thereof

The invention relates to novel N,N'-disubstituted 2-thioxo-7-oxa-1,3-diaza-spiro[4.4]nonan-4-one-androgen receptor (AR) antagonists, an anticancer agent, a pharmaceutical composition, a medicament, and a method for treating prostate cancer. 4-[3-(4-Cyano-3-trifluoromethyl-phenyl)-4-oxo-2-thioxo-7-oxa-1,3-diaza-spiro[4.4]non-1-yl]-2-fluoro-benzamide of general formula 1 and enantiomer thereof 

Cyclic N,N'-diarylthioureas and N,N&#x2032;-diarylureas-androgen receptor antagonists, anticancer agent, method for preparation and use thereof

The present invention relates to novel neuraminidase activity inhibitors and use thereof for prophylaxis and treatment of influenza infection, that is to fluorosubstituted4-acetamido-5-guanidino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylic acids and their esters of the general formula 1, pharmaceutically acceptable salts and/or hydrates thereof, wherein R is hydrogen, an optionally substituted C-Calkyl, C-Calkenyl or C-Calkynyl; Rf is CHF or CHF. A pharmaceutical composition is provided, a method for its preparation, as well as a method for prophylaxis and treatment of viral diseases.

Fluorosubstituted-(3R,4R,5S)-5-guanidino 4-acetamido-3-(pentan-3-yloxy)cyclohex-1-enecarboxylic acid compound, ester and use thereof

Growing community of inventors

Encinitas, CA, United States of America

Alexandre Vasilievich Ivachtchenko